Search results
Showing 7441 to 7455 of 7707 results
Multiple myeloma - bortezomib (consolidation therapy) [ID529]
Discontinued [GID-TAG320]
This guidance has been updated and replaced by NICE interventional procedures guidance 737.
October 2018: The device used in this procedure (CyPass) has been withdrawn by the manufacturer Alcon, because of concerns about its long-term safety. Further details can be found in the Voluntary Field Safety Notice issued by Alcon. Surgeons are advised not to implant this device, to return any unused devices to Alcon and to consider reviewing any patients who have already been implanted with CyPass. Therefore NICE has decided to withdraw its guidance. NICE would consider whether to issue new guidance on ab interno supraciliary microstent insertion with phacoemulsification for primary open-angle glaucoma should evidence using an appropriately CE marked device become available.
This guidance has been updated and replaced by the NICE guideline on asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN).
Asthma: diagnosis, monitoring and chronic asthma management (NG80)
This guideline has been updated and replaced by NICE guideline NG245.
This guidance has been updated and replaced by the NICE guideline on asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN).
This guidance has been updated and replaced by the NICE guideline on asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN).
This guidance has been updated and replaced by the NICE guideline on asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN).
In development [GID-TA10843] Expected publication date: TBC
Discontinued [GID-TA11399]
Nivolumab for adjuvant treatment of localised renal cell carcinoma [ID6362]
Discontinued [GID-TA11421]
Discontinued [GID-TA10316]